Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update

Xilio Therapeutics, Inc. (NASDAQ:XLO) saw a significant decline in short interest during the month of September. As of September 15th, there was short interest totalling 14,800 shares, a decline of 52.3% from the August 31st total of 31,000 shares. Based on an average daily trading volume, of 144,500 shares, the short-interest ratio is presently 0.1 days. Currently, 0.1% of the shares of the company are sold short.

Institutional Investors Weigh In On Xilio Therapeutics

A hedge fund recently raised its stake in Xilio Therapeutics stock. Renaissance Technologies LLC grew its position in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) by 18.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 295,000 shares of the company’s stock after buying an additional 45,554 shares during the quarter. Renaissance Technologies LLC owned approximately 0.80% of Xilio Therapeutics worth $280,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 54.29% of the company’s stock.

Xilio Therapeutics Price Performance

Xilio Therapeutics stock opened at $0.76 on Friday. Xilio Therapeutics has a 12-month low of $0.49 and a 12-month high of $2.89. The stock has a market capitalization of $33.53 million, a PE ratio of -0.30 and a beta of -0.10. The firm has a 50 day simple moving average of $0.86 and a 200-day simple moving average of $0.97.

Xilio Therapeutics (NASDAQ:XLO) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.01). The firm had revenue of $2.36 million during the quarter, compared to analyst estimates of $30.00 million. On average, analysts forecast that Xilio Therapeutics will post -1.26 earnings per share for the current fiscal year.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.